Ravuconazole CAS NO 182760-06-1 Inquire about Ravuconazole
Tecoland supplies Ravuconazole bulk active pharmaceutical ingredient (API) to the pharmaceutical industry. Our Ravuconazole is manufactured by cGMP compliant facility. Welcome to contact us for further details including current DMF status for the product and up to date regulatory status of the manufacturing facility. We look forward to assisting you with your research and development projects.
What is Ravuconazole?
Ravuconazole is a potent triazole antifungal. The drug has shown to have a similar spectrum of activity to voriconazole, with an increased half-life. However, ravuconazole has limited activity against species of Fusarium, Scedosporium, and Zygomycetes.
Mechanism of Action:
As with all azole antifungal agents, ravuconazole works principally by inhibition of cytochrome P450 14a-demethylase (P45014DM). This enzyme is in the sterol biosynthesis pathway that leads from lanosterol to ergosterol [2092].
Ravuconazole Drug Interactions:
(R)-warfarin:
The therapeutic efficacy of (R)-warfarin can be increased when used in combination with Ravuconazole.
(S)-Warfarin：
The therapeutic efficacy of (S)-Warfarin can be increased when used in combination with Ravuconazole.
4-hydroxycoumarin：
The therapeutic efficacy of 4-hydroxycoumarin can be increased when used in combination with Ravuconazole.
Acenocoumarol：
The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Ravuconazole.
Agmatine：
The therapeutic efficacy of Ravuconazole can be increased when used in combination with Agmatine.
Almasilate：
Almasilate can cause a decrease in the absorption of Ravuconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aloglutamol：
Aloglutamol can cause a decrease in the absorption of Ravuconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminium：
Aluminium can cause a decrease in the absorption of Ravuconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminium acetoacetate：
Aluminium acetoacetate can cause a decrease in the absorption of Ravuconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminium glycinate：
Aluminium glycinate can cause a decrease in the absorption of Ravuconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Disclaimer:
Information on this page is provided for general information purposes. You should not make a clinical treatment decision based on information contained in this page without consulting other references including the package insert of the drug, textbooks and where relevant, expert opinion. We cannot be held responsible for any errors you make in administering drugs mentioned on this page, nor for use of any erroneous information contained on this page.